All In Biotech

Drug Trial Radar · NCT01732822

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 13,885 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

13,885

Actual

Start

Dec 4, 2012

Primary completion

Sep 26, 2016

Study completion Sep 26, 2016

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Conditions

  • Peripheral Artery Disease

Interventions

  • TicagrelorDrug

    Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets

  • ClopidogrelDrug

    Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Cardiovascular (CV) Death/MI/Ischemic StrokeTime frame: From randomization to PACD, an average of 2.5 years

Locations

776 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Alexander City, Alabama

  • Research Site

    Auburn, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Cottonwood, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Fort Smith, Arkansas

  • Research Site

    Jonesboro, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Berkeley, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Chula Vista, California

  • Research Site

    El Cajon, California

  • Research Site

    Fresno, California

  • Research Site

    La Jolla, California

  • Research Site

    La Mesa, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Long Beach, California

  • Research Site

    Mission Viejo, California

  • Research Site

    Moreno Valley, California

  • Research Site

    Northridge, California

  • Research Site

    Oceanside, California

  • Research Site

    Orange, California

  • Research Site

    Palo Alto, California

  • Research Site

    Sacramento, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Stockton, California

  • Research Site

    Torrance, California

  • Research Site

    Torrance, California

  • Research Site

    Loveland, Colorado

Showing 40 of 776 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.